Related references
Note: Only part of the references are listed.Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR/EULAR criteria): a prospective study aimed at identification of diagnostic and prognostic biomarkers as well as therapeutic targets
Daphne de Launay et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon
Sanna Rosengren et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis
Y. Tanaka et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production
Timothy P. LaBranche et al.
ARTHRITIS AND RHEUMATISM (2012)
A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2012)
Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study
Georg Schett et al.
ARTHRITIS AND RHEUMATISM (2012)
Regulation of Inflammatory Responses in Tumor Necrosis Factor-Activated and Rheumatoid Arthritis Synovial Macrophages by JAK Inhibitors
Anna Yarilina et al.
ARTHRITIS AND RHEUMATISM (2012)
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
Roy Fleischmann et al.
ARTHRITIS AND RHEUMATISM (2012)
The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells
Keisuke Maeshima et al.
ARTHRITIS AND RHEUMATISM (2012)
Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation
Hideyuki Yoshida et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
Apostolos Kontzias et al.
CURRENT OPINION IN PHARMACOLOGY (2012)
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald F. van Vollenhoven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Phase II Study of Tofacitinib (CP-690,550) Combined With Methotrexate in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Yoshiya Tanaka et al.
ARTHRITIS CARE & RESEARCH (2011)
A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis
Kristine L. Stump et al.
ARTHRITIS RESEARCH & THERAPY (2011)
An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis.
Michael E. Weinblatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Treatment of Rheumatoid Arthritis With a Syk Kinase Inhibitor A Twelve-Week, Randomized, Placebo-Controlled Trial
Michael E. Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2008)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
Share Paper
